Qrativ (Mayo Clinic - Nference Joint Venture)

qrativ is reinventing the way treatments for diseases with unmet medical need are discovered and developed. formed by mayo clinic and nference, qrativ combines nference’s knowledge synthesis platform, and mayo clinic’s medical expertise and clinical data to enable systematic drug purposing. starting in the early stages of drug development, qrativ partners can leverage the company’s drug purposing platform, darwin.ai, to search for all possible uses of a drug candidate, including identifying potential rare disease indications and find subsets of patients who may respond favorably to a given candidate. through these partnerships, qrativ will aim to maximize every drug’s potential for as many patients and diseases as possible.